Israel Englander’s Karyopharm Therapeutics KPTI Stock Holding History

Israel Englander’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$352K	Buy	+36,000	New	+$312K	﹤0.01%	5027
2021 Q1	–	Sell	-2,000	Closed	-$464K	–	6253
2020 Q4	$464K	Sell	2,000 -647	-24%	-$150K	﹤0.01%	4245
2020 Q3	$580	Buy	+2,647	New	+$647K	﹤0.01%	3500
2020 Q2	–	Sell	-1,000	Closed	-$288K	–	4398
2020 Q1	$288K	Buy	+1,000	New	+$276K	﹤0.01%	3195
2018 Q4	–	Sell	-1,633	Closed	-$417K	–	3965
2018 Q3	$417K	Buy	+1,633	New	+$451K	﹤0.01%	3332
2018 Q2	–	Sell	-10,000	Closed	-$2.01M	–	3985
2018 Q1	$2.01M	Buy	+10,000	New	+$1.99M	﹤0.01%	2315

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's KPTI Position: Q2 2026 in Review

Israel Englander reduced its Karyopharm Therapeutics (KPTI) stake by 27% in Q2 2026, selling an estimated $997K and leaving 305,676 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3482.

Israel Englander first reported a position in KPTI in Q4 2013 and has held it in 45 quarters since. The position peaked at $38.6M in Q4 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Israel Englander held 305,676 shares of Karyopharm Therapeutics worth $2.99M as of Q2 2026.
Israel Englander sold 114,895 Karyopharm Therapeutics shares in Q2 2026, an estimated $997K.
Karyopharm Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3482 holding.
Israel Englander first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 45 quarters since.
Israel Englander's Karyopharm Therapeutics position peaked at $38.6M in Q4 2020.
96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.